Pazopanib induced pigmented lesions of the scrotum and the face in a patient with metastatic renal cancer

J Eur Acad Dermatol Venereol. 2019 Oct;33(10):e361-e362. doi: 10.1111/jdv.15657. Epub 2019 May 20.

Authors

M Kostaki¹, A Stathopoulou¹, M Plaka¹, A Zaras¹, E Chatzidimitriou¹, A Dimitrakopoulou¹, E Christofidou¹, D Polydorou¹, A Stratigos¹

Affiliation

¹ First Department of Dermatology-Venereology of Medical School of Athens University, Andreas Syggros Hospital, Athens 16121, Greece.

PMID: 31066082
DOI: 10.1111/jdv.15657

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Angiogenesis Inhibitors / adverse effects
Angiogenesis Inhibitors / therapeutic use
Antineoplastic Agents / adverse effects*
Antineoplastic Agents / therapeutic use
Face / pathology*
Humans
Indazoles
Male
Middle Aged
Pigmentation Disorders / chemically induced*
Pyrimidines / adverse effects*
Pyrimidines / therapeutic use
Receptors, Vascular Endothelial Growth Factor / antagonists & inhibitors
Scrotum / pathology*
Sulfonamides / adverse effects*
Sulfonamides / therapeutic use

Substances

Angiogenesis Inhibitors
Antineoplastic Agents
Indazoles
Pyrimidines
Sulfonamides
pazopanib
Receptors, Vascular Endothelial Growth Factor